A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma ; day:14 ; month:8 ; year:2019 ; pages:1-11
Investigational new drugs ; (14.8.2019), 1-11
- Urheber
-
Takahashi, Shunji
Uemura, Motohide
Kimura, Tomokazu
Kawasaki, Yoshihide
Takamoto, Atsushi
Yamaguchi, Akito
Melhem-Bertrandt, Amal
Gartner, Elaina M.
Inoue, Takashi
Akazawa, Rio
Kadokura, Takeshi
Tanikawa, Toshiki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-019-00844-x
- URN
-
urn:nbn:de:101:1-2020011821443121394757
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.01.8023, 20:04 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Takahashi, Shunji
- Uemura, Motohide
- Kimura, Tomokazu
- Kawasaki, Yoshihide
- Takamoto, Atsushi
- Yamaguchi, Akito
- Melhem-Bertrandt, Amal
- Gartner, Elaina M.
- Inoue, Takashi
- Akazawa, Rio
- Kadokura, Takeshi
- Tanikawa, Toshiki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding
Management of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma: Expert Opinion from an Indian Panel via Delphi Consensus Method
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Recent advances in medical therapy for metastatic urothelial cancer
Enhanced metastatic potential in the MB49 urothelial carcinoma model
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain
Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors
Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations
Polatuzumab Vedotin: First Global Approval
Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding
Management of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma: Expert Opinion from an Indian Panel via Delphi Consensus Method
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Recent advances in medical therapy for metastatic urothelial cancer
Enhanced metastatic potential in the MB49 urothelial carcinoma model
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain
Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors
Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations
Polatuzumab Vedotin: First Global Approval
Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding
Management of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma: Expert Opinion from an Indian Panel via Delphi Consensus Method
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Recent advances in medical therapy for metastatic urothelial cancer
Enhanced metastatic potential in the MB49 urothelial carcinoma model
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain
Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors
Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations